Tag: Johnson & Johnson
J&J takeover of Verb Surgical : J&J strikes deal with Verily for full ownership in robotic surgery company
J&J takeover of Verb Surgical : Johnson & Johnson (J&J) has agreed to take full ownership in US robotic surgery company Verb Surgical by acquiring ... Read More
Janssen to acquire skin disease drug candidate bermekimab from XBiotech
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational ... Read More
Janssen bags Stelara FDA approval for ulcerative colitis treatment
Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged approval from the US Food and Drug ... Read More
Janssen bags Xarelto FDA approval to prevent blood clots in acutely ill patients
Xarelto FDA approval : The Janssen Pharmaceutical Companies of Johnson & Johnson has secured approval from the US Food and Drug Administration (FDA) for Xarelto ... Read More
Janssen’s Ponesimod OPTIMUM trial in MS meets primary endpoint
Ponesimod OPTIMUM trial results : Johnson & Johnson's Janssen Pharmaceutical said that the phase 3 OPTIMUM clinical trial evaluating ponesimod yielded positive results compared to ... Read More
Guselkumab meets primary endpoints in phase 3 psoriatic arthritis program
Johnson & Johnson’s Janssen Pharmaceutical said that its IL-23 p19 inhibitor TREMFYA (guselkumab) met the primary endpoints of American College of Rheumatology 20% improvement (ACR20) ... Read More
J&J wraps up $2.1bn acquisition of Japanese cosmetics company Ci:z Holdings
US healthcare conglomerate Johnson & Johnson (J&J) completed its previously announced JPY230 billion ($2.1 billion) acquisition of Japanese cosmetics company Ci:z Holdings. Headquartered in Tokyo, ... Read More
Amgen seeks FDA approval for infliximab biosimilar ABP 710
Amgen has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to Johnson & ... Read More
Janssen depression medication esketamine nasal spray yields mixed results in phase 3 trial
Janssen Pharmaceutical Companies of Johnson & Johnson depression medication esketamine nasal spray did not meet expectations in a phase 3 trial in patients with treatment-resistant ... Read More
Janssen bags EC approval for daratumumab for multiple myeloma
Janssen Pharmaceutical Companies of Johnson & Johnson has secured marketing authorization for its monoclonal antibody Darzalex (daratumumab) from the European Commission (EC) as initial therapy ... Read More